Chimerix Inc (CMRX)
0.9529
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
0.9548
0.00 (0.00%)
After-Hours: 20:00
Chimerix Research and Development Expense (Quarterly): 15.64M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 15.64M |
September 30, 2023 | 17.40M |
June 30, 2023 | 16.93M |
March 31, 2023 | 18.82M |
December 31, 2022 | 19.28M |
September 30, 2022 | 15.26M |
June 30, 2022 | 18.05M |
March 31, 2022 | 19.04M |
December 31, 2021 | 34.34M |
September 30, 2021 | 13.82M |
June 30, 2021 | 13.80M |
March 31, 2021 | 11.86M |
December 31, 2020 | 8.687M |
September 30, 2020 | 10.02M |
June 30, 2020 | 8.578M |
March 31, 2020 | 8.949M |
December 31, 2019 | 7.493M |
September 30, 2019 | 7.453M |
June 30, 2019 | 13.83M |
March 31, 2019 | 13.52M |
December 31, 2018 | 15.28M |
September 30, 2018 | 11.89M |
June 30, 2018 | 13.71M |
March 31, 2018 | 14.36M |
Date | Value |
---|---|
December 31, 2017 | 12.91M |
September 30, 2017 | 12.16M |
June 30, 2017 | 11.64M |
March 31, 2017 | 12.74M |
December 31, 2016 | 11.70M |
September 30, 2016 | 12.25M |
June 30, 2016 | 13.76M |
March 31, 2016 | 20.94M |
December 31, 2015 | 31.85M |
September 30, 2015 | 26.50M |
June 30, 2015 | 21.86M |
March 31, 2015 | 17.44M |
December 31, 2014 | 15.67M |
September 30, 2014 | 13.33M |
June 30, 2014 | 8.092M |
March 31, 2014 | 8.292M |
December 31, 2013 | 6.283M |
September 30, 2013 | 5.319M |
June 30, 2013 | 6.276M |
March 31, 2013 | 6.783M |
December 31, 2012 | 6.283M |
September 30, 2012 | 7.748M |
June 30, 2012 | 9.082M |
March 31, 2012 | 6.642M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.453M
Minimum
Sep 2019
34.34M
Maximum
Dec 2021
14.70M
Average
13.83M
Median
Jun 2019
Research and Development Expense (Quarterly) Benchmarks
UFP Technologies Inc | -- |
Dentsply Sirona Inc | 42.00M |
Arbutus Biopharma Corp | 17.56M |
Pacira BioSciences Inc | 19.46M |
Karyopharm Therapeutics Inc | 39.38M |